Dixon Mitchell Investment Counsel Inc. Purchases Shares of 866,380 Certara, Inc. $CERT

Dixon Mitchell Investment Counsel Inc. acquired a new stake in shares of Certara, Inc. (NASDAQ:CERT) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 866,380 shares of the company’s stock, valued at approximately $10,587,000. Dixon Mitchell Investment Counsel Inc. owned 0.54% of Certara as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Wasatch Advisors LP boosted its holdings in Certara by 45.7% in the second quarter. Wasatch Advisors LP now owns 13,532,882 shares of the company’s stock valued at $158,335,000 after acquiring an additional 4,244,230 shares during the last quarter. Marshall Wace LLP increased its stake in Certara by 1,430.6% during the second quarter. Marshall Wace LLP now owns 1,512,343 shares of the company’s stock worth $17,694,000 after acquiring an additional 1,413,538 shares during the last quarter. Ameriprise Financial Inc. increased its stake in Certara by 27.1% during the second quarter. Ameriprise Financial Inc. now owns 5,460,630 shares of the company’s stock worth $63,889,000 after acquiring an additional 1,165,064 shares during the last quarter. Fort Washington Investment Advisors Inc. OH purchased a new position in shares of Certara in the 3rd quarter worth about $11,899,000. Finally, Mackenzie Financial Corp raised its holdings in shares of Certara by 47.7% in the 2nd quarter. Mackenzie Financial Corp now owns 2,648,549 shares of the company’s stock worth $30,988,000 after purchasing an additional 855,222 shares during the period. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

CERT has been the subject of a number of research reports. Barclays reiterated an “equal weight” rating and set a $8.00 target price on shares of Certara in a report on Friday. Craig Hallum downgraded shares of Certara from a “buy” rating to a “hold” rating and set a $10.00 price objective for the company. in a research note on Friday, February 27th. KeyCorp dropped their price objective on shares of Certara from $13.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, January 8th. TD Cowen reissued a “buy” rating on shares of Certara in a research note on Thursday, February 26th. Finally, Stephens reduced their target price on shares of Certara from $15.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, December 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $11.10.

Certara Stock Performance

Certara stock opened at $7.04 on Tuesday. The stock’s 50 day moving average price is $8.14 and its 200 day moving average price is $9.72. The firm has a market capitalization of $1.12 billion, a PE ratio of -704.00 and a beta of 1.50. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.05 and a current ratio of 2.05. Certara, Inc. has a one year low of $6.04 and a one year high of $15.38.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.02). The firm had revenue of $103.65 million during the quarter, compared to analyst estimates of $103.23 million. Certara had a negative net margin of 0.38% and a positive return on equity of 4.20%. The firm’s revenue was up 3.2% compared to the same quarter last year. During the same period last year, the business earned $0.15 EPS. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. As a group, sell-side analysts expect that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Certara Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.